Table 1.
Demographic and baseline characteristics
| Safety population (SAF, N = 453) | Safety PGA population (SAFT, N = 444) | |
|---|---|---|
| Age (years) | ||
| Mean (SD) | 18.3 ± 6.6 | 18.4 ± 6.5 |
| Age group, n (%) | ||
| <18 years | 286 (63.1) | 277 (62.4) |
| ≥18 years | 167 (36.9) | 167 (37.6) |
| 9–11 years | 18 (4.0) | 9 (2.0) |
| Gender, n (%) | ||
| Male | 227 (50.1) | 227 (51.1) |
| Female | 226 (49.9) | 217 (48.9) |
| Race, n (%) | ||
| White | 432 (95.4) | 424 (95.5) |
| Black or African American | 12 (2.6) | 11 (2.5) |
| Asian | 3 (0.7) | 3 (0.7) |
| American Indian or Alaska Native | 1 (0.2) | 1 (0.2) |
| Native Hawaiian or Other Pacific Islander | 3 (0.7) | 3 (0.7) |
| Multiple | 2 (0.4) | 2 (0.5) |
| Other | 0 | 0 |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 47 (10.4) | 44 (9.9) |
| Not Hispanic or Latino | 406 (89.6) | 400 (90.1) |
| Skin phototype, n (%) | ||
| Type I | 13 (2.9) | 13 (2.9) |
| Type II | 188 (41.5) | 182 (41.0) |
| Type III | 184 (40.6) | 183 (41.2) |
| Type IV | 53 (11.7) | 52 (11.7) |
| Type V | 7 (1.5) | 7 (1.6) |
| Type VI | 2 (0.4) | 1 (0.2) |
| Missing | 6 (1.3) | 6 (1.4) |
| Baseline inflammatory facial lesion count | ||
| n | 453 | 444 |
| Mean (SD) | 15.0 | 15.2 |
| Baseline non‐inflammatory facial lesion count | ||
| n | 453 | 444 |
| Mean (SD) | 58.2 ± 36.7 | 58.5 ± 37.0 |
| Baseline inflammatory truncal lesion count | ||
| n | 446 | 444 |
| Missing | 7 | 0 |
| Mean (SD) | 43.4 ± 28.6 | 43.5 ± 28.5 |
| Baseline non‐inflammatory truncal lesion count | ||
| Missing | 7 | 0 |
| Mean (SD) | 56.1 ± 39.5 | 56.3 ± 39.4 |
Safety Population (SAF): All patients that were randomized and applied the study drug at least once. It includes all patients with facial acne/trunk acne and facial acne/without truncal acne.
Safety PGA Population (SAFT): All patients that were randomized and applied the study drug at least once on the trunk. It includes all patients with facial acne/truncal acne.